EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Long‐Term Efficacy and Safety of Oleogel‐ S10 (Birch Triterpenes) for Pediatric Patients With Epidermolysis Bullosa

Eli Sprecher iD, Mauricio Torres-Pradilla, Maria Florencia Fernandez, Christine Bodemer, Anna L Bruckner iD, Silvia Maria de Macedo Barbosa, Andrea Diociaiuti iD, Anna E Martinez, Francis Palisson, Miloš Nikolić iD, Asunción Vicente, Raúl de Lucas iD und 5 weitere

Pediatric Dermatology · 2026

DOI: 10.1111/pde.70224 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Dermatology, 2026. Verfasst von Eli Sprecher und 16 weiteren Autor:innen. Beteiligte Einrichtung: Tel Aviv Sourasky Medical Center and Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Wound Healing, Epidermolysis Bullosa, Organic Chemicals, Triterpenes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chiesi Farmaceutici.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives Pediatric patients with epidermolysis bullosa (EB) experience lifelong complications, and wound healing is an important treatment goal. In the phase III EASE study (NCT03068780), Oleogel‐S10 accelerated wound healing in EB. This prespecified subgroup analysis evaluated the long‐term efficacy and safety of Oleogel‐S10 in patients aged < 18 years from EASE.

Methods

EASE comprised a 90‐day double‐blind phase (DBP) and 24‐month open‐label phase (OLP). In the DBP, patients were randomized 1:1 to receive Oleogel‐S10 or control gel; all patients could enter the OLP and receive Oleogel‐S10. Endpoints in this analysis included wound healing, total body wound burden, dressing change burden, and safety.

Results

Overall, 156 pediatric patients were enrolled into the DBP (Oleogel‐S10: n = 74; Control gel: n = 82); 147 entered the OLP. Oleogel‐S10 resulted in 44.6% of pediatric patients with first complete target wound closure within 45 days, versus 25.6% with control gel (relative risk [95% CI]: 1.70 [1.11, 2.60], p = 0.012). Mean absolute body surface area percentage scores were 12.5% at DBP baseline and 5.3% at OLP Month 24 for the Oleogel‐S10 group. Significantly more patients treated with Oleogel‐S10 (38%) no longer required daily dressing changes versus control gel (9%) at DBP Day 90. Similar proportions of patients experienced adverse events in the Oleogel‐S10 and control gel groups in the DBP, with most mild or moderate.

Conclusions

These analyses of pediatric patients demonstrated accelerated wound healing, reduced frequency of dressing changes, and sustained reduction in wound burden up to 27 months. Long‐term safety was consistent with the overall EASE population. Trial Registration: NCT03068780, EudraCT 2016‐002066‐32; registered 3 March 2017; https://clinicaltrials.gov/study/NCT03068780 and https://www.clinicaltrialsregister.eu/ctr‐search/trial/2016‐002066‐32/GB

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wound HealingEpidermolysis BullosaOrganic ChemicalsTriterpenesHumansChildFemaleMaleDouble-Blind MethodAdolescentTreatment OutcomeChild, Preschool

Stichwörter der Autor:innen

birch triterpenes/birch bark extract/Oleogel‐S10dressing change burdenepidermolysis bullosapediatricwound healing

Substanzen

oleogelsOrganic ChemicalsTriterpenes

Autor:innen und Institutionen

  • Tel Aviv Sourasky Medical Center and Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Department of Dermatology, Hospital de San José, Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia.
  • Fundacion Respirar, Centro Medico Dra. De Salvo, Capital Federal, Buenos Aires, Argentina.
  • Department of Dermatology, Expert Centre for Genodermatoses (MAGEC) Necker-Enfants Malades Hospital, University Paris Centre, APHP, Paris, France.
  • Department of Dermatology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Pain and Palliative Care Unit, Instituto da Criança, Hospital das Clínicas, Faculty of Medicine, Universidade de São Paulo, São Paulo, São Paulo, Brazil.

ORCID-Profile: Eli Sprecher, Anna L Bruckner, Andrea Diociaiuti, Miloš Nikolić, Raúl de Lucas, Johannes S Kern

Förderung

  • Chiesi Farmaceutici

Zitieren

APA

Sprecher, E., Torres-Pradilla, M., Fernandez, M. F., Bodemer, C., Bruckner, A. L., de Macedo Barbosa, S. M., Diociaiuti, A., Martinez, A. E., Palisson, F., Nikolić, M., Vicente, A., de Lucas, R., Temin, N. T., Löwe, S., Kern, J. S., Murrell, D. F., & EASE Study Group (2026). Long‐Term Efficacy and Safety of Oleogel‐ S10 (Birch Triterpenes) for Pediatric Patients With Epidermolysis Bullosa. Pediatric Dermatology. https://doi.org/10.1111/pde.70224

Vancouver

Sprecher E, Torres-Pradilla M, Fernandez MF, Bodemer C, Bruckner AL, de Macedo Barbosa SM, et al. Long‐Term Efficacy and Safety of Oleogel‐ S10 (Birch Triterpenes) for Pediatric Patients With Epidermolysis Bullosa. Pediatric Dermatology. 2026. doi:10.1111/pde.70224

BibTeX
@article{Sprecher2026,
  author = {Sprecher, Eli and Torres-Pradilla, Mauricio and Fernandez, Maria Florencia and Bodemer, Christine and Bruckner, Anna L and de Macedo Barbosa, Silvia Maria and Diociaiuti, Andrea and Martinez, Anna E and Palisson, Francis and Nikolić, Miloš and Vicente, Asunción and de Lucas, Raúl and Temin, Noemi Toiber and Löwe, Sandra and Kern, Johannes S and Murrell, Dédée F and EASE Study Group, EASE Study Group},
  title = {Long‐Term Efficacy and Safety of Oleogel‐ S10 (Birch Triterpenes) for Pediatric Patients With Epidermolysis Bullosa},
  journal = {Pediatric Dermatology},
  year = {2026},
  doi = {10.1111/pde.70224}
}
Kostenlos starten →